BCAX
Bicara Therapeutics Inc.
Healthcare — Biotechnology
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
None
13 analysts
$18.20
$-0.41 (-2.20%)
Target:
$31.46
(72.9%)
Price History
52-Week Range
Sign in to add BCAX to a watchlist or set price alerts.
Fundamentals
| Market Cap | $1.90B |
| P/E Ratio (TTM) | - |
| Forward P/E | -7.96 |
| EPS (TTM) | $-2.77 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -32.34% |
| Debt/Equity | 0.28 |
| Recommendation | None |
| Analyst Target | $31.46 |
| Analysts | 13 |
| Next Earnings | Aug 11, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 91.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $29.90 |
| 52-Week Low | $8.74 |
| 50-Day Avg | $22.47 |
| 200-Day Avg | $18.48 |
| Avg Volume | 724.6K |
| Volume | 137.5K |
Performance Analysis
NEUTRALBCAX presents a mixed picture with both positive and negative indicators.
~
Trading at 45% of its 52-week range.
-
RSI at 91.3 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 13 analysts.
+
Average analyst target of $31.46 implies 72.9% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 12:59 UTC
Back to Screener Export Report